Ozanimod

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 360 publications

Sphingosine-1-phosphate (S1P) signaling as a novel therapeutic target for alcohol abuse.

Sphingosine-1-phosphate (S1P) signaling as a novel therapeutic target for alcohol abuse.

Journal: Research square

Published: February 27, 2026

Real-world experience of ozanimod in adults with multiple sclerosis.

Real-world experience of ozanimod in adults with multiple sclerosis.

Journal: Neurodegenerative disease management

Published: January 30, 2026

Ozanimod and other sphingosine-1-phosphate receptor 1 modulators normalize neuropathic injury-enhanced inhibition of central lateral amygdala neurons expressing corticotropin-releasing hormone.

Ozanimod and other sphingosine-1-phosphate receptor 1 modulators normalize neuropathic injury-enhanced inhibition of central lateral amygdala neurons expressing corticotropin-releasing hormone.

Journal: Neuropharmacology

Published: January 22, 2026

Pharmacological properties and clinical efficacy of sphingosine 1-phosphate (S1P) receptor modulator, Ozanimod (ZEPOSIA®)

Pharmacological properties and clinical efficacy of sphingosine 1-phosphate (S1P) receptor modulator, Ozanimod (ZEPOSIA®)

Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica

Published: January 04, 2026

Neutropenia after ocrelizumab treatment in patients with multiple sclerosis: A single-centre case series and systematic review of literature.

Neutropenia after ocrelizumab treatment in patients with multiple sclerosis: A single-centre case series and systematic review of literature.

Journal: Multiple sclerosis and related disorders

Published: January 03, 2026

Effect of Sphingosine-1-Phosphate Receptor Modulators on Insulin Resistance: A Review.

Effect of Sphingosine-1-Phosphate Receptor Modulators on Insulin Resistance: A Review.

Journal: The Annals of pharmacotherapy

Published: January 03, 2026

The comparative efficacy of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis: Updated meta-regression estimates by patient subgroup.

The comparative efficacy of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis: Updated meta-regression estimates by patient subgroup.

Journal: Multiple sclerosis and related disorders

Published: December 20, 2025

Sphingosine 1-Phosphate (S1P) Receptor Modulators as an Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Sphingosine 1-Phosphate (S1P) Receptor Modulators as an Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Journal: Digestive diseases and sciences

Published: December 02, 2025

Addressing autoimmune comorbidities in multiple sclerosis: A case report of ulcerative colitis remission in a patient treated with cladribine tablets.

Addressing autoimmune comorbidities in multiple sclerosis: A case report of ulcerative colitis remission in a patient treated with cladribine tablets.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: December 01, 2025

Sphingosine-1-phosphate (S1P) signaling as a novel therapeutic target for alcohol abuse.

Sphingosine-1-phosphate (S1P) signaling as a novel therapeutic target for alcohol abuse.

Journal: bioRxiv : the preprint server for biology

Published: November 26, 2025

Comparative effectiveness of anti-CD20 therapies and S1P receptor modulators in late-onset multiple sclerosis: real-world evidence from the MSBase registry.

Comparative effectiveness of anti-CD20 therapies and S1P receptor modulators in late-onset multiple sclerosis: real-world evidence from the MSBase registry.

Journal: Therapeutic advances in neurological disorders

Published: November 09, 2025

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial.

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: November 05, 2025

Showing 1-12 of 360

Last Updated: 04/28/2026